Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Issues

Volume 27, Issue 2
15 January 2021
Issue Cover
All Issues
  • Cover Image

    Cover Image

    issue cover
    The cover shows a biopsy from a patient with metastatic non-small cell lung cancer with a cryptic EML4-ALK fusion. This fusion was not detected by ALK IHC and FISH due to the complex nature of the rearrangement; however, whole genome sequencing and RNA-seq identified the variant, and the patient had an excellent response to crizotinib. For details, see the article by Tsang and colleagues on page 522 of this issue.
  • PDF Icon PDF LinkTable of Contents
  • PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265

Highlights

Selected Articles from This Issue
View articletitled, Selected Articles from This Issue
Open the PDF for in another window

CCR Translations

Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?
Amy S. Clark; Igor Makhlin; Angela DeMichele
View articletitled, Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?
Open the PDF for in another window
Senescent T Cells as a Resistance Mechanism to Lung Cancer Immunotherapy
Diego Salas-Benito; Iñaki Eguren-Santamaria; Miguel F. Sanmamed
View articletitled, Senescent T Cells as a Resistance Mechanism to Lung Cancer Immunotherapy
Open the PDF for in another window
A New Generation of “Magic Bullets” for Molecular Targeting of Cancer
Jacek Capala; Charles A. Kunos
View articletitled, A New Generation of “Magic Bullets” for Molecular Targeting of Cancer
Open the PDF for in another window
CDK12 Deficiency and the Immune Microenvironment in Prostate Cancer
Tamara L. Lotan; Emmanuel S. Antonarakis
View articletitled, <em>CDK12</em> Deficiency and the Immune Microenvironment in Prostate Cancer
Open the PDF for in another window

Reviews

Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies
Matthew S. Waitkus; Hai Yan
View articletitled, Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies
Open the PDF for in another window
Sebaceous Carcinoma Epidemiology and Genetics: Emerging Concepts and Clinical Implications for Screening, Prevention, and Treatment
Michael R. Sargen; Gabriel J. Starrett; Eric A. Engels; Elizabeth K. Cahoon; Margaret A. Tucker; Alisa M. Goldstein
View articletitled, Sebaceous Carcinoma Epidemiology and Genetics: Emerging Concepts and Clinical Implications for Screening, Prevention, and Treatment
Open the PDF for in another window
Author Choice
Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop
Kristen L. Mueller; Marc R. Theoret; Steven J. Lemery; Laleh Amiri-Kordestani; Charlotte E. Ariyan; Michael B. Atkins; Donald A. Berry; Christian U. Blank; Angela M. DeMichele; Patrick M. Forde; Nageatte Ibrahim; Patricia Keegan; Tara C. Mitchell; Rebecca A. Moss; Caroline Robert; Rajeshwari Sridhara; Janis M. Taube; Michael T. Tetzlaff; Jennifer A. Wargo; Keith T. Flaherty; Michael J. Kaplan; Suzanne L. Topalian; Ashley F. Ward; Marc S. Hurlbert
View articletitled, Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop
Open the PDF for in another window

Clinical Trial Brief Report

Early Response to First-Line Anti–PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial
Conrad-Amadeus Voltin; Jasmin Mettler; Lutz van Heek; Helen Goergen; Horst Müller; Christian Baues; Ulrich Keller; Julia Meissner; Karolin Trautmann-Grill; Andrea Kerkhoff; Michael Fuchs; Stephanie Sasse; Bastian von Tresckow; Markus Dietlein; Peter Borchmann; Andreas Engert; Carsten Kobe; Paul J. Bröckelmann
View articletitled, Early Response to First-Line Anti–PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial
Open the PDF for in another window

Clinical Trials: Targeted Therapy

Author Choice
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer
Yen-Shen Lu; Keun Seok Lee; Tsu-Yi Chao; Ling-Ming Tseng; Imjai Chitapanarux; Shin-Cheh Chen; Chien-Ting Liu; Joohyuk Sohn; Jee Hyun Kim; Yuan-Ching Chang; Youngsen Yang; Kanjana Shotelersuk; Kyung Hae Jung; Roberta Valenti; Cassandra Slader; Melissa Gao; Yeon Hee Park
View articletitled, A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer
Supplementary data
Open the PDF for in another window
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
Sara M. Tolaney; Young-Hyuck Im; Emiliano Calvo; Yen-Shen Lu; Erika Hamilton; Andres Forero-Torres; Thomas Bachelot; Michela Maur; Angelica Fasolo; Ralph Tiedt; Lisa Nardi; Uz Stammberger; Ahmed M. Abdelhady; Shiling Ruan; Soo Chin Lee
View articletitled, Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR<sup>+</sup> Advanced Breast Cancer
Supplementary data
Open the PDF for in another window
Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response
Fatima Karzai; Stephanie M. Walker; Scott Wilkinson; Ravi A. Madan; Joanna H. Shih; Maria J. Merino; Stephanie A. Harmon; David J. VanderWeele; Lisa M. Cordes; Nicole V. Carrabba; John R. Bright; Nicolas T. Terrigino; Guinevere Chun; Marijo Bilusic; Anna Couvillon; Amy Hankin; Monique N. Williams; Rosina T. Lis; Huihui Ye; Peter L. Choyke; James L. Gulley; Adam G. Sowalsky; Baris Turkbey; Peter A. Pinto; William L. Dahut
View articletitled, Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response
Supplementary data
Open the PDF for in another window
Author Choice
Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Antoine Hollebecque; Stefania Salvagni; Ruth Plummer; Nicolas Isambert; Patricia Niccoli; Jaume Capdevila; Giuseppe Curigliano; Victor Moreno; Patricia Martin-Romano; Eric Baudin; Marina Arias; Sheila Mora; Juan de Alvaro; Jorge Di Martino; Josep L. Parra-Palau; Tania Sánchez-Pérez; Ida Aronchik; Ellen H. Filvaroff; Manisha Lamba; Zariana Nikolova; Johann S. de Bono
View articletitled, Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Supplementary data
Open the PDF for in another window
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
Komal Jhaveri; Matthew T. Chang; Dejan Juric; Cristina Saura; Valentina Gambardella; Anton Melnyk; Manish R. Patel; Vincent Ribrag; Cynthia X. Ma; Raid Aljumaily; Philippe L. Bedard; Jasgit C. Sachdev; Lara Dunn; Helen Won; John Bond; Surai Jones; Heidi M. Savage; Maurizio Scaltriti; Timothy R. Wilson; Michael C. Wei; David M. Hyman
View articletitled, Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <em>PIK3CA</em>-Mutant Cancers
Supplementary data
Open the PDF for in another window

Clinical Trials: Immunotherapy

Author Choice
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors
Martin Gutierrez; Victor Moreno; Kimberley M. Heinhuis; Anthony J. Olszanski; Anna Spreafico; Michael Ong; Quincy Chu; Richard D. Carvajal; José Trigo; Maria Ochoa de Olza; Mariano Provencio; Filip Yves De Vos; Filippo De Braud; Stephen Leong; Deanne Lathers; Rui Wang; Palani Ravindran; Yan Feng; Praveen Aanur; Ignacio Melero
View articletitled, OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors
Supplementary data
Open the PDF for in another window
CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1–positive B-Cell Lymphoma
Hui Liu; Wen Lei; Chaoting Zhang; Chunmei Yang; Juying Wei; Qunyi Guo; Xiaojun Guo; Zhilu Chen; Ying Lu; Ken H. Young; Zheming Lu; Wenbin Qian
View articletitled, CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1–positive B-Cell Lymphoma
Supplementary data
Open the PDF for in another window
Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors
Osama E. Rahma; Joshua E. Reuss; Anita Giobbie-Hurder; Ghazaleh Shoja E Razavi; Osama Abu-Shawer; Pooja Mehra; Seema Gupta; Richard Simon; Samir N. Khleif
View articletitled, Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors
Supplementary data
Open the PDF for in another window

Precision Medicine and Imaging

Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
Roberto Ferrara; Marie Naigeon; Edouard Auclin; Boris Duchemann; Lydie Cassard; Jean-Mehdi Jouniaux; Lisa Boselli; Jonathan Grivel; Aude Desnoyer; Laura Mezquita; Matthieu Texier; Caroline Caramella; Lizza Hendriks; David Planchard; Jordi Remon; Sabina Sangaletti; Claudia Proto; Marina C. Garassino; Jean-Charles Soria; Aurelien Marabelle; Anne-Laure Voisin; Siham Farhane; Benjamin Besse; Nathalie Chaput
View articletitled, Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
Supplementary data
Open the PDF for in another window
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial
Elena Guerini-Rocco; Kathryn P. Gray; Caterina Fumagalli; Marta Rita Reforgiato; Isabella Leone; Paola Rafaniello Raviele; Elisabetta Munzone; Roswitha Kammler; Patrick Neven; Erika Hitre; Guy Jerusalem; Edda Simoncini; Andrea Gombos; Ines Deleu; Per Karlsson; Stefan Aebi; Jacquie Chirgwin; Vincenzo Di Lauro; Alastair Thompson; Marie-Pascale Graas; Matthew Barber; Christel Fontaine; Sibylle Loibl; Joaquín Gavilá; Katsumasa Kuroi; Bettina Müller; Seamus O’Reilly; Angelo Di Leo; Aron Goldhirsch; Giuseppe Viale; Massimo Barberis; Meredith M. Regan; Marco Colleoni
View articletitled, Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial
Supplementary data
Open the PDF for in another window
Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study
Alfredo Rivas-Delgado; Ferran Nadeu; Anna Enjuanes; Sebastián Casanueva-Eliceiry; Pablo Mozas; Laura Magnano; Natalia Castrejón de Anta; Jordina Rovira; Ivan Dlouhy; Silvia Martín; Miguel Osuna; Sonia Rodríguez; Marc Simó; Magda Pinyol; Tycho Baumann; Silvia Beà; Olga Balagué; Julio Delgado; Neus Villamor; Xavier Setoain; Elías Campo; Eva Giné; Armando López-Guillermo
View articletitled, Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study
Supplementary data
Open the PDF for in another window
Uncovering Clinically Relevant Gene Fusions with Integrated Genomic and Transcriptomic Profiling of Metastatic Cancers
Erica S. Tsang; Cameron J. Grisdale; Erin Pleasance; James T. Topham; Karen Mungall; Caralyn Reisle; Caleb Choo; Marcus Carreira; Reanne Bowlby; Joanna M. Karasinska; Daniel MacMillan; Laura M. Williamson; Eric Chuah; Richard A. Moore; Andrew J. Mungall; Yongjun Zhao; Basile Tessier-Cloutier; Tony Ng; Sophie Sun; Howard J. Lim; David F. Schaeffer; Daniel J. Renouf; Stephen Yip; Janessa Laskin; Marco A. Marra; Steven J.M. Jones; Jonathan M. Loree
View articletitled, Uncovering Clinically Relevant Gene Fusions with Integrated Genomic and Transcriptomic Profiling of Metastatic Cancers
Supplementary data
Open the PDF for in another window

Translational Cancer Mechanisms and Therapy

A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy
Brian H. Santich; Sarah M. Cheal; Mahiuddin Ahmed; Michael R. McDevitt; Ouathek Ouerfelli; Guangbin Yang; Darren R. Veach; Edward K. Fung; Mitesh Patel; Daniela Burnes Vargas; Aiza A. Malik; Hong-Fen Guo; Pat B. Zanzonico; Sebastien Monette; Adam O. Michel; Charles M. Rudin; Steven M. Larson; Nai K. Cheung
View articletitled, A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy
Supplementary data
Open the PDF for in another window
Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity
Bangxing Hong; Valerie Chapa; Uksha Saini; Puneet Modgil; David E. Cohn; Guangan He; Zahid H. Siddik; Anil K. Sood; Yuanqing Yan; Karuppaiyah Selvendiran; Guangsheng Pei; Zhongming Zhao; Ji Young Yoo; Balveen Kaur
View articletitled, Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity
Supplementary data
Open the PDF for in another window
Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer
Adam R. Wolfe; Ryan Robb; Ahmad Hegazi; Laith Abushahin; Linlin Yang; Duan-Liang Shyu; Jose G. Trevino; Zobeida Cruz-Monserrate; John R. Jacob; Kamalakannan Palanichamy; Arnab Chakravarti; Terence M. Williams
View articletitled, Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer
Supplementary data
Open the PDF for in another window
Author Choice
Characterizing CDK12-Mutated Prostate Cancers
Pasquale Rescigno; Bora Gurel; Rita Pereira; Mateus Crespo; Jan Rekowski; Mattia Rediti; Maialen Barrero; Joaquin Mateo; Diletta Bianchini; Carlo Messina; Maria D. Fenor de la Maza; Khobe Chandran; Juliet Carmichael; Christina Guo; Alec Paschalis; Adam Sharp; George Seed; Ines Figueiredo; Maryou Lambros; Susana Miranda; Ana Ferreira; Claudia Bertan; Ruth Riisnaes; Nuria Porta; Wei Yuan; Suzanne Carreira; Johann S. de Bono
View articletitled, Characterizing CDK12-Mutated Prostate Cancers
Supplementary data
Open the PDF for in another window
Hematopoietic Stem Cell Transplantation Positively Affects the Natural History of Cancer in Nijmegen Breakage Syndrome
Beata Wolska-Kusnierz; Agata Pastorczak; Wojciech Fendler; Anna Wakulinska; Bozena Dembowska-Baginska; Edyta Heropolitanska-Pliszka; Barbara Piątosa; Barbara Pietrucha; Krzysztof Kałwak; Marek Ussowicz; Anna Pieczonka; Katarzyna Drabko; Monika Lejman; Sylwia Koltan; Jolanta Gozdzik; Jan Styczynski; Alina Fedorova; Natalia Miakova; Elena Deripapa; Larysa Kostyuchenko; Zdenka Krenova; Eva Hlavackova; Andrew R. Gennery; Karl-Walter Sykora; Sujal Ghosh; Michael H. Albert; Dmitry Balashov; Mary Eapen; Peter Svec; Markus G. Seidel; Sara S. Kilic; Agnieszka Tomaszewska; Ewa Wiesik-Szewczyk; Alexandra Kreins; Johann Greil; Jochen Buechner; Bendik Lund; Hanna Gregorek; Krystyna Chrzanowska; Wojciech Mlynarski
View articletitled, Hematopoietic Stem Cell Transplantation Positively Affects the Natural History of Cancer in Nijmegen Breakage Syndrome
Supplementary data
Open the PDF for in another window
Author Choice
Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor–Positive Breast Cancers
Reema S. Wahdan-Alaswad; Susan M. Edgerton; Hiba Salem; Hyun Min Kim; Aik Choon Tan; Jessica Finlay-Schultz; Elizabeth A. Wellberg; Carol A. Sartorius; Britta M. Jacobsen; Bryan R. Haugen; Bolin Liu; Ann D. Thor
View articletitled, Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor–Positive Breast Cancers
Supplementary data
Open the PDF for in another window
BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia
Haley E. Ramsey; Dalton Greenwood; Susu Zhang; Merrida Childress; Maria P. Arrate; Agnieszka E. Gorska; Londa Fuller; Yue Zhao; Kristy Stengel; Melissa A. Fischer; Matthew C. Stubbs; Phillip C.C. Liu; Kelli Boyd; Jeffrey C. Rathmell; Scott W. Hiebert; Michael R. Savona
View articletitled, BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia
Supplementary data
Open the PDF for in another window
Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses
David H. Aggen; Casey R. Ager; Aleksandar Z. Obradovic; Nivedita Chowdhury; Ali Ghasemzadeh; Wendy Mao; Matthew G. Chaimowitz; Zoila A. Lopez-Bujanda; Catherine S. Spina; Jessica E. Hawley; Matthew C. Dallos; Cheng Zhang; Vinson Wang; Hu Li; Xinzheng V. Guo; Charles G. Drake
View articletitled, Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses
Supplementary data
Open the PDF for in another window
Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia
Yoon-Chi Han; Jennifer Kahler; Nicole Piché-Nicholas; Wenyue Hu; Stephane Thibault; Fan Jiang; Mauricio Leal; Madan Katragadda; Andreas Maderna; Russell Dushin; Nadira Prashad; Manoj B. Charati; Tracey Clark; L. Nathan Tumey; Xingzhi Tan; Andreas Giannakou; Edward Rosfjord; Hans-Peter Gerber; Lioudmila Tchistiakova; Frank Loganzo; Christopher J. O'Donnell; Puja Sapra
View articletitled, Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia
Supplementary data
Open the PDF for in another window
Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion
Christian Watermann; Helen Pasternack; Christian Idel; Julika Ribbat-Idel; Johannes Brägelmann; Patrick Kuppler; Anne Offermann; Danny Jonigk; Mark Philipp Kühnel; Andreas Schröck; Eva Dreyer; Christian Rosero; Jacqueline Nathansen; Anna Dubrovska; Lars Tharun; Jutta Kirfel; Barbara Wollenberg; Sven Perner; Rosemarie Krupar
View articletitled, Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion
Supplementary data
Open the PDF for in another window
RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP–negative Glioblastoma
Anna Esteve-Codina; Francesc Alameda; Cristina Carrato; Estela Pineda; Oriol Arpí; Maria Martinez-García; Mar Mallo; Marta Gut; Marc Dabad; Avelina Tortosa; Sonia Del Barco; Jaume Capellades; Josep Puig; Oscar Gallego; Teresa Pujol; Laura Oleaga; Miquel Gil-Gil; Cristian de Quintana-Schmidt; Izaskun Valduvieco; Anna Martinez-Cardús; Beatriz Bellosillo; Ana Maria Muñoz-Marmol; Anna Esteve; Marta Domenech; Angels Camins; Jordi Craven-Bartle; Salvador Villa; Jordi Marruecos; Sira Domenech; Nuria de la Iglesia; Carmen Balana
View articletitled, RNA sequencing and Immunohistochemistry Reveal <em>ZFN7</em> as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP–negative Glioblastoma
Supplementary data
Open the PDF for in another window

Advertisement

Breaking
Lung Cancer Immunotherapies Earn FDA Approval
SCOTUS Weighs FDA’s Ban of Some E-cigarettes
Treatment with Low-Energy Electric Fields Ups Pancreatic Cancer Survival
View more recent articles
Latest News
Prevention and Screening Preclude 80% of Cancer Deaths
Tumors Leverage Liver Metabolism to Fuel Growth With Fructose
French Liquid Biopsy Program Delivering Personalized Care
View more recent articles
Research Watch
The Liver X Receptor Axis Balances Intestinal Regeneration and Tumorigenesis
Oncolytic Virotherapy Plus Nivolumab Is Safe in Muscle-Invasive Bladder Cancer
Specialized Fibroblasts Shape T-Cell Environments in Lung Cancer
View more recent articles

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.

  • Online ISSN 1557-3265
  • Print ISSN 1078-0432

AACR Journals

 

 

  • Copyright © 2023 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept